1
|
Liu S, Zha C, Nacro K, Hu M, Cui W, Yang YL, Bhatt U, Sambandam A, Isherwood M, Yet L, Herr MT, Ebeltoft S, Hassler C, Fleming L, Pechulis AD, Payen-Fornicola A, Holman N, Milanowski D, Cotterill I, Mozhaev V, Khmelnitsky Y, Guzzo PR, Sargent BJ, Molino BF, Olson R, King D, Lelas S, Li YW, Johnson K, Molski T, Orie A, Ng A, Haskell R, Clarke W, Bertekap R, O’Connell J, Lodge N, Sinz M, Adams S, Zaczek R, Macor JE. Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors. ACS Med Chem Lett 2014; 5:760-5. [PMID: 25050161 DOI: 10.1021/ml500053b] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Accepted: 05/13/2014] [Indexed: 11/30/2022] Open
Abstract
A series of 4-bicyclic heteroaryl 1,2,3,4-tetrahydroisoquinoline inhibitors of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) was discovered. The synthesis and structure-activity relationship (SAR) of these triple reuptake inhibitors (TRIs) will be discussed. Compound 10i (AMR-2), a very potent inhibitor of SERT, NET, and DAT, showed efficacy in the rat forced-swim and mouse tail suspension models with minimum effective doses of 0.3 and 1 mg/kg (po), respectively. At efficacious doses in these assays, 10i exhibited substantial occupancy levels at the three transporters in both rat and mouse brain. The study of the metabolism of 10i revealed the formation of a significant active metabolite, compound 13.
Collapse
Affiliation(s)
- Shuang Liu
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Congxiang Zha
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Kassoum Nacro
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Min Hu
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Wenge Cui
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Yuh-Lin Yang
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Ulhas Bhatt
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Aruna Sambandam
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | | | - Larry Yet
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Michael T. Herr
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Sarah Ebeltoft
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Carla Hassler
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Linda Fleming
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | | | | | - Nicholas Holman
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | | | - Ian Cotterill
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Vadim Mozhaev
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Yuri Khmelnitsky
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Peter R. Guzzo
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Bruce J. Sargent
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Bruce F. Molino
- AMRI, 26 Corporate Circle, Albany, New York 12212, United States
| | - Richard Olson
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Dalton King
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Snjezana Lelas
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Yu-Wen Li
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Kim Johnson
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Thaddeus Molski
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Anitra Orie
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Alicia Ng
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Roy Haskell
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Wendy Clarke
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Robert Bertekap
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Jonathan O’Connell
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Nicholas Lodge
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Michael Sinz
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Stephen Adams
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - Robert Zaczek
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| | - John E. Macor
- Bristol Myers Squibb R&D, 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States
| |
Collapse
|
2
|
Affiliation(s)
- Zhicai Yang
- Medicinal Chemistry Department, AMRI,
26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098,
United States
| | - Xiaomin Jin
- Medicinal Chemistry Department, AMRI,
26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098,
United States
| | - Michael Guaciaro
- Medicinal Chemistry Department, AMRI,
26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098,
United States
| | - Bruce F. Molino
- Medicinal Chemistry Department, AMRI,
26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098,
United States
| |
Collapse
|
3
|
Yang Z, Jin X, Guaciaro M, Molino BF, Mocek U, Reategui R, Rhea J, Morley T. The Revised Structure, Total Synthesis, and Absolute Configuration of Streptophenazine A. Org Lett 2011; 13:5436-9. [DOI: 10.1021/ol202005u] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Zhicai Yang
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098, United States, Lead Discovery, AMRI, 22215 26th Avenue SE, Bothell, Washington 98021, United States, and Aquapharm Biodiscovery Ltd., European Centre for Marine Biotechnology, Dunstaffnage, Oban, Argyll, PA37 1QA, Scotland, U.K
| | - Xiaomin Jin
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098, United States, Lead Discovery, AMRI, 22215 26th Avenue SE, Bothell, Washington 98021, United States, and Aquapharm Biodiscovery Ltd., European Centre for Marine Biotechnology, Dunstaffnage, Oban, Argyll, PA37 1QA, Scotland, U.K
| | - Michael Guaciaro
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098, United States, Lead Discovery, AMRI, 22215 26th Avenue SE, Bothell, Washington 98021, United States, and Aquapharm Biodiscovery Ltd., European Centre for Marine Biotechnology, Dunstaffnage, Oban, Argyll, PA37 1QA, Scotland, U.K
| | - Bruce F. Molino
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098, United States, Lead Discovery, AMRI, 22215 26th Avenue SE, Bothell, Washington 98021, United States, and Aquapharm Biodiscovery Ltd., European Centre for Marine Biotechnology, Dunstaffnage, Oban, Argyll, PA37 1QA, Scotland, U.K
| | - Ursula Mocek
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098, United States, Lead Discovery, AMRI, 22215 26th Avenue SE, Bothell, Washington 98021, United States, and Aquapharm Biodiscovery Ltd., European Centre for Marine Biotechnology, Dunstaffnage, Oban, Argyll, PA37 1QA, Scotland, U.K
| | - Ricardo Reategui
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098, United States, Lead Discovery, AMRI, 22215 26th Avenue SE, Bothell, Washington 98021, United States, and Aquapharm Biodiscovery Ltd., European Centre for Marine Biotechnology, Dunstaffnage, Oban, Argyll, PA37 1QA, Scotland, U.K
| | - Joshua Rhea
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098, United States, Lead Discovery, AMRI, 22215 26th Avenue SE, Bothell, Washington 98021, United States, and Aquapharm Biodiscovery Ltd., European Centre for Marine Biotechnology, Dunstaffnage, Oban, Argyll, PA37 1QA, Scotland, U.K
| | - Tim Morley
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098, United States, Lead Discovery, AMRI, 22215 26th Avenue SE, Bothell, Washington 98021, United States, and Aquapharm Biodiscovery Ltd., European Centre for Marine Biotechnology, Dunstaffnage, Oban, Argyll, PA37 1QA, Scotland, U.K
| |
Collapse
|
4
|
Affiliation(s)
- Zhicai Yang
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098
| | - Phung Tang
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098
| | - Jolicia F. Gauuan
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098
| | - Bruce F. Molino
- Medicinal Chemistry Department, AMRI, 26 Corporate Circle, P.O. Box 15098, Albany, New York 12212-5098
| |
Collapse
|
5
|
Cherney RJ, Brogan JB, Mo R, Lo YC, Yang G, Miller PB, Scherle PA, Molino BF, Carter PH, Decicco CP. Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists. Bioorg Med Chem Lett 2008; 19:597-601. [PMID: 19131247 DOI: 10.1016/j.bmcl.2008.12.062] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2008] [Revised: 12/12/2008] [Accepted: 12/16/2008] [Indexed: 10/21/2022]
Abstract
A series of trisubstituted cyclohexanes was designed, synthesized and evaluated as CC chemokine receptor 2 (CCR2) antagonists. This led to the identification of two distinct substitution patterns about the cyclohexane ring as potent and selective CCR2 antagonists. Compound 36 exhibited excellent binding (CCR2 IC(50)=2.4 nM) and functional antagonism (calcium flux IC(50)=2.0 nM and chemotaxis IC(50)=5.1 nM).
Collapse
Affiliation(s)
- Robert J Cherney
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Hirsh AJ, Molino BF, Zhang J, Astakhova N, Geiss WB, Sargent BJ, Swenson BD, Usyatinsky A, Wyle MJ, Boucher RC, Smith RT, Zamurs A, Johnson MR. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem 2006; 49:4098-115. [PMID: 16821771 DOI: 10.1021/jm051134w] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Amiloride (1), the prototypical epithelial sodium channel (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmonary function in patients with the genetic disorder cystic fibrosis. This study was conducted to synthesize and identify more potent, less reversible ENaC blockers, targeted for aerosol therapy and possessing minimal systemic renal activity. A series of novel 2-substituted acylguanidine analogues of amiloride were synthesized and evaluated for potency and reversibility on bronchial ENaC. All compounds tested were more potent and less reversible at blocking sodium-dependent short-circuit current than amiloride. Compounds 30-34 showed the greatest potency on ENaC with IC(50) values below 10 nM. A regioselective difference in potency was found (compounds 30, 39, and 40), whereas no stereospecific (compounds 33, 34) difference in potency on ENaC was displayed. Lead compound 32 was 102-fold more potent and 5-fold less reversible than amiloride and displayed the lowest IC(50) value ever reported for an ENaC blocker.
Collapse
Affiliation(s)
- Andrew J Hirsh
- Parion Sciences Inc., 2525 Meridian Parkway, Suite 260, Durham, North Carolina 27713, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
|
8
|
|
9
|
|
10
|
Klein SI, Molino BF, Czekaj M, Gardner CJ, Chu V, Brown K, Sabatino RD, Bostwick JS, Kasiewski C, Bentley R, Windisch V, Perrone M, Dunwiddie CT, Leadley RJ. Design of a new class of orally active fibrinogen receptor antagonists. J Med Chem 1998; 41:2492-502. [PMID: 9651154 DOI: 10.1021/jm9801096] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The integrin receptor recognition sequence Arg-Gly-Asp was successfully used as a template from which to develop a series of potent, selective, orally active, peptide-based fibrinogen receptor antagonists with a long duration of action. Simple modifications centered on the Arg and Gly residues quickly led to a modified peptide (1) with significantly enhanced ability to inhibit in vitro platelet aggregation. Substitution of the guanidino group in 1 by piperidine provided 3, which showed not only a further increase in potency but also a modest degree of oral efficacy. Finally, exploration of the nature of the C-terminal amino acid, with respect to its side-chain functionality and the carboxy terminus, yielded a group of molecules that showed excellent in vitro potency for inhibiting platelet aggregation, excellent integrin selectivity, a high level of oral efficacy, and an extended duration of action.
Collapse
Affiliation(s)
- S I Klein
- Department of Cardiovascular Research, Rhône-Poulenc Rorer Central Research, Collegeville, Pennsylvania 19426, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Klein SI, Czekaj M, Molino BF, Chu V. Conformationally flexible platelet aggregation inhibitors based on the tetrapeptide Arg-Gly-Asp-Arg. Eur J Med Chem 1997. [DOI: 10.1016/s0223-5234(99)80069-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
12
|
|
13
|
Klein SI, Dener JM, Molino BF, Gardner CJ, D'Alisa R, Dunwiddie CT, Kasiewski C, Leadley RJ. O-benzyl hydroxyproline as a bioisostere for Phe-Pro: Novel dipeptide thrombin inhibitors. Bioorg Med Chem Lett 1996. [DOI: 10.1016/0960-894x(96)00404-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
14
|
Klein SI, Molino BF, Czekaj M, Dener JS, Leadley RJ, Sabatino R, Dunwiddie CT, Chu V. Non-peptide fibrinogen receptor antagonists based upon a 4-substituted piperidine scaffold. Bioorg Med Chem Lett 1996. [DOI: 10.1016/0960-894x(96)00236-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Pendley CE, Fitzpatrick LR, Ewing RW, Molino BF, Martin GE. The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat. J Pharmacol Exp Ther 1993; 265:1348-54. [PMID: 8510013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
L-365,260, a nonpeptide antagonist of gastrin/CCK-B receptors, was evaluated in receptor binding, antisecretory and gastrointestinal damage assays. L-365,260 binds potently and stereo-selectively to gastrin and CCK-B sites in guinea pig tissue. In contrast, L-365,260 binds to the isolated canine parietal cell gastrin receptor weakly, and without stereoselectivity. In the pylorus-ligated rat, low doses of L-365,260, given i.v., attenuated pentagastrin-stimulated acid secretion, whereas higher doses were required to inhibit both histamine-stimulated and basal acid secretion. In an aspirin-induced gastric damage model, L-365,260 was 2.4-fold less potent than the standard histamine H2 antagonist cimetidine in preventing gastric damage when given i.v., and was 8.3-fold less potent than cimetidine when given p.o. Moreover, the ED50 value for L-365,260, given i.v., in prevention of aspirin-induced gastric damage (11.5 mg/kg) agreed well with its ED50 value for inhibition of basal acid secretion (12.6 mg/kg). At doses as great as 100 mg/kg p.o., neither L-365,260 nor cimetidine had an effect on ethanol-induced gastric damage. L-365,260, although p.o. less bioavailable relative to cimetidine in the aspirin gastric damage model, was as potent as cimetidine in the prevention of cysteamine-induced duodenal ulcers in the rat. We conclude that the gastrin/CCK-B receptor antagonist L-365,260, at doses supramaximal for the inhibition of pentagastrin-stimulated secretory responses in vivo, inhibits gastrointestinal damage in models of peptic ulcer disease by an antisecretory mechanism of action.
Collapse
Affiliation(s)
- C E Pendley
- Department of Pharmacology, Rhône-Poulenc Rorer Central Research, Collegeville, Pennsylvania
| | | | | | | | | |
Collapse
|
16
|
|
17
|
|